Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le vendredi 22 novembre 2019
Doi : 10.1016/j.jaad.2019.09.085
accepted : 27 September 2019
Sunscreen and frontal fibrosing alopecia: A review

Gabrielle Robinson, MD a, Amy McMichael, MD b, Steve Q. Wang, MD c, Henry W. Lim, MD a,
a Department of Dermatology, Henry Ford Hospital, Detroit, Michigan 
b Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina 
c Department of Dermatology, Memorial Sloan-Kettering Cancer Center, Basking Ridge, New Jersey 

Correspondence to: Henry W. Lim, MD, Department of Dermatology, Henry Ford Hospital–New Center One, 3031 West Grand Blvd, Suite 800, Detroit, MI 48202.Department of DermatologyHenry Ford Hospital–New Center One3031 West Grand Blvd, Suite 800DetroitMI48202

Frontal fibrosing alopecia (FFA) is a cicatricial alopecia of unknown etiology. The incidence of FFA appears to be increasing with time, leading to suspicion of a possible environmental trigger. Observational studies have reported a positive correlation between facial sunscreen use and FFA. This finding raises the question of whether sunscreen use plays a role in disease development. In this article, we review the available literature on the association of sunscreen with FFA. There is insufficient evidence to establish a direct causal relationship between sunscreen and FFA. Further studies are required to better characterize the role of sunscreen and the environment in the pathogenesis of this unique disease.

The full text of this article is available in PDF format.

Key words : alopecia, frontal fibrosing alopecia, hair, hair loss, inflammatory hair disorder, lichen planopilaris, primary lymphocytic cicatricial alopecia, scarring, sunscreen, titanium dioxide, ultraviolet filter

Abbreviations used : FFA, TiO2 , UV

 Reprints not available from the authors.
 Funding sources: None.
 Conflicts of interest: Drs Robinson and Wang have no conflicts of interest to disclose. Dr McMichael has served as an investigator for Aclaris Therapeutics, Cassiopea, Concert Pharmaceuticals, Incyte, Procter and Gamble Pharmaceuticals, and Samumed and has served as a consultant for Aclaris Therapeutics, Allergan, Bioniz Therapeutics, Cassiopea, Covance, eResearch Technology, Inc, Galderma, Incyte, Johnson & Johnson, KeraNetics, Merck & Co, Inc, Pfizer, Procter & Gamble Pharmaceuticals, and Samumed. She has received grants from Allergan, Concert Pharmaceuticals, and Procter & Gamble and receives royalties from Informa Healthcare and UpToDate. Dr Lim has served as an investigator for Estée Lauder, Ferndale Pharma Group, Unigen, Incyte, and Beiersdorf; he has also served as a consultant for Pierre Fabre, ISDIN, and Ferndale Pharma Group and has participated as a speaker in an educational session for Pierre Fabre and Eli Lilly.
 IRB approval status: Not applicable.

© 2019  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline